Baclofen

Baclofen is a prescription muscle relaxant and antispastic drug that works as a selective agonist of the GABA-B receptor, one of the receptors for gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter of the central nervous system ^[1][3]. Chemically it is beta-(4-chlorophenyl)-GABA, essentially a molecule of GABA carrying an added chlorophenyl group that helps the compound cross the blood-brain barrier, which GABA itself does poorly ^[1]. It is a small crystalline compound used clinically as a racemic mixture ^[1].

The drug was synthesized in 1962 by the Swiss chemist Heinrich Keberle at Ciba-Geigy, originally in the hope of treating epilepsy ^[1]. Its anticonvulsant effects proved underwhelming, but its ability to relax skeletal muscle and reduce spasticity stood out, and baclofen was subsequently developed and approved for that indication, reaching the market in the 1970s ^[1]. A historical curiosity is that it was approved as a medicine before the GABA-B receptor it acts on had even been identified, and it remains the only GABA-B agonist approved by the U.S. Food and Drug Administration ^[1].

Baclofen's central use is the management of chronic, disabling muscle spasticity, particularly the spasticity that accompanies multiple sclerosis and injury or disease of the spinal cord ^[1]. For severe cases that do not respond to oral therapy, the drug can be infused directly into the cerebrospinal fluid through a surgically implanted intrathecal pump, an approach that delivers strong antispastic effect at much smaller amounts; intrathecal baclofen has also been explored in patients with severe disorders of consciousness ^[4][5]. Beyond spasticity, baclofen has drawn attention as an off-label treatment for alcohol use disorder; a Cochrane systematic review concluded that it probably lowers the risk of relapse and increases the percentage of abstinent days, mainly among people who have already been detoxified, though it did not beat placebo on every measure ^[2]. It has additionally been studied for opioid withdrawal and other conditions ^[1].

Baclofen is a generic, prescription-only medicine that appears on the World Health Organization's List of Essential Medicines ^[1]. It is most commonly given as oral tablets, with the intrathecal pump reserved for severe spasticity, and compounded topical and other formulations exist as well ^[1]. A clinically important caution is that stopping the drug abruptly, especially after long-term or intrathecal use, can trigger a serious withdrawal syndrome, so treatment is tapered rather than halted suddenly ^[1].

Baclofen is a GABA-B receptor agonist and muscle relaxant that commonly causes sedation, drowsiness, dizziness, weakness and fatigue, and overdose can cause respiratory depression, coma and seizures; these effects are intensified by alcohol and other CNS depressants. Abrupt discontinuation after regular use can trigger a serious withdrawal syndrome with hallucinations, seizures and rebound spasticity, so it must be tapered. Dose reduction is needed in kidney impairment.

Baclofen is a GABA-B receptor agonist and its labeling documents additive central nervous system and respiratory depression when combined with other CNS depressants; alcohol, opioids, benzodiazepines, and sedating antihistamines all compound its sedation. Tricyclic antidepressants may potentiate its muscle-relaxant effect, producing marked hypotonia. Antihypertensive agents can have their blood-pressure-lowering effect exaggerated, and in patients with renal impairment baclofen accumulates because it is largely renally cleared, so drugs that reduce renal function raise the risk of toxicity and encephalopathy. Abrupt discontinuation, especially of intrathecal baclofen, is a documented cause of seizures, hallucinations, and rebound spasticity, so it must be tapered. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Baclofen was first synthesized in 1962 by the Swiss chemist Heinrich Keberle at Ciba-Geigy, who designed it as a lipophilic derivative of the neurotransmitter GABA, adding a chlorophenyl group in the hope of creating an anticonvulsant able to cross the blood-brain barrier. It proved disappointing as an antiepileptic but was found to relax skeletal muscle, and it entered clinical use in the 1970s for the spasticity of multiple sclerosis and spinal cord injury. In 1984 the pharmacologists Norman Bowery and colleagues used baclofen as the defining tool to identify the GABA-B receptor, establishing it as a distinct class from the fast GABA-A receptor. Intrathecal delivery by an implanted pump was later developed for severe spasticity, and the drug has more recently drawn attention as an off-label treatment for alcohol use disorder.

Baclofen holds a well-established place in neurology and rehabilitation medicine as a first-line agent for relieving disabling muscle spasticity, and it appears on the World Health Organization's List of Essential Medicines. Patients and clinicians appreciate that, for severe cases, the intrathecal pump can deliver strong relief at a fraction of the oral dose while limiting sedation. In pharmacology it is remembered as the compound that opened the door to the entire GABA-B receptor field, giving it a lasting scientific legacy. Its off-label use for alcohol dependence has generated considerable interest and debate, with reviews finding modest and mixed benefit; careful dosing and gradual withdrawal are emphasized to avoid rebound effects.